ESTRO 2025 - Abstract Book

S2099

Clinical - Urology

ESTRO 2025

Results: At end of treatment, lymphopenia was found in 72.9% of patients who received pelvic irradiation (p<0.05). Variables also related were IMRT (60%) and hypofractionation (61.1%). However, lymphopenia had no impact on OS, PFS, recurrence, toxicity, or infection rates (Figure 1). With a median follow-up of 86 months, 5 and 10-year OS were 90% and 65%. 5 and 10-year CSS were 96% and 92%, respectively, 10 patients dead by prostate cancer.